Proton-pump inhibitors: understanding the complications and risks (original) (raw)

• Turner, T. Proton pump inhibitors. Drugwatch https://www.drugwatch.com/proton-pump-inhibitors/ (2017).
• Statista. Top 20 pharmaceutical products by sales worldwide in 2014 (in billions US dollars). Statista https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/ (2017).
• Lessell, S. Omeprazole (correction of omepraxole) and ocular damage. Concerns on safety of drug are unwarranted. BMJ 316, 7124–7167 (1998).
  Google Scholar
• Stolte, M., Bethke, B., Rühl, G. & Ritter, M. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z. Gastroenterol. 30, 134–138 (1992).
  CAS PubMed Google Scholar
• Fiocca, R. et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment. Pharmacol. Ther. 36, 959–971 (2012). A controlled study on the long-term effect of PPIs on endocrine and exocrine gastric cells.
  Article CAS PubMed Google Scholar
• Cats, A. et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum. Pathol. 31, 684–690 (2000).
  Article CAS PubMed Google Scholar
• Lamberts, R., Brunner, G. & Solcia, E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 64, 205–213 (2001).
  Article CAS PubMed Google Scholar
• Lundell, L., Vieth, M., Gibson, F., Nagy, P. & Kahrilas, P. J. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment. Pharmacol. Ther. 42, 649–663 (2015). This systematic review reports on long-term PPI-induced moderate hypergastrinaemia in most patients and an increased prevalence of enterochromaffin-like cell hyperplasia; Helicobacter pylori -positive patients receiving long-term PPI therapy were exposed to a higher risk of corpus atrophy than were H. pylori -negative patients.
  Article CAS PubMed Google Scholar
• Schubert, M. L. Gastric acid secretion. Curr. Opin. Gastroenterol. 32, 452–460 (2016).
  Article PubMed Google Scholar
• Reimer, C., Søndergaard, B., Hilsted, L. & Bytzer, P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 137, 80–87 (2009).
  Article CAS PubMed Google Scholar
• Hongo, M., Fujimoto, K. & Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J. Gastroenterol. 45, 618–624 (2010).
  Article CAS PubMed Google Scholar
• Martin, F. C., Chenevix-Trench, G. & Yeomans, N. D. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment. Pharmacol. Ther. 44, 915–925 (2016).
  Article CAS PubMed Google Scholar
• Tran-Duy, A., Spaetgens, B., Hoes, A. W., de Wit, N. J. & Stehouwer, C. D. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 14, 1706–1719 (2016). The latest systematic review and meta-analysis reporting that PPI use increases the incidence of fundic gland polyps; a small effect on gastric cancer is biased by confounding factors.
  Article CAS PubMed Google Scholar
• Worthley, D. L. et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61, 774–779 (2012).
  Article CAS PubMed Google Scholar
• Yanaru-Fujisawa, R. et al. Familial fundic gland polyposis with gastric cancer. Gut 61, 1103–1104 (2012).
  Article PubMed Google Scholar
• Sanduleanu, S. et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur. J. Clin. Invest. 31, 802–811 (2001).
  Article CAS PubMed Google Scholar
• Savarino, V., Dulbecco, P. & Savarino, E. Are proton pump inhibitors really so dangerous? Dig. Liver Dis. 48, 851–859 (2016).
  Article CAS PubMed Google Scholar
• Waldum, H. L., Hauso, Ø., Brenna, E., Qvigstad, G. & Fossmark, R. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man? Scand. J. Gastroenterol. 51, 767–773 (2016).
  Article CAS PubMed Google Scholar
• Jianu, C. S. et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment. Pharmacol. Ther. 36, 644–649 (2012).
  Article CAS PubMed Google Scholar
• Pregun, I. et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 84, 22–28 (2011).
  Article CAS PubMed Google Scholar
• Wong, H. et al. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. Pathol. Oncol. Res. 16, 87–91 (2010).
  Article PubMed Google Scholar
• Han, Y. M. et al. Role of proton pump inhibitors in preventing hypergastrinemia-associated carcinogenesis and in antagonizing the trophic effect of gastrin. J. Physiol. Pharmacol. 66, 159–167 (2015). Experimental evidence of anti-carcinogenetic effects of PPIs — these results are awaiting clinical confirmation.
  CAS PubMed Google Scholar
• Poulsen, A. H. et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br. J. Cancer. 100, 1503–1507 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Singh, M., Dhindsa, G., Friedland, S. & Triadafilopoulos, G. Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic caracteristics of colon adenomas. Aliment. Pharmacol. Ther. 26, 1051–1061 (2007).
  Article CAS PubMed Google Scholar
• Robertson, D. J. et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology 133, 755–760 (2007).
  Article PubMed Google Scholar
• Kearns, M. D., Boursi, B. & Yang, Y. X. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol. 46, 80–84 (2017).
  Article PubMed PubMed Central Google Scholar
• Kuipers, E. J. et al. Increase of _Helicobacter pylori_-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am. J. Gastroenterol. 90, 1401–1406 (1995).
  CAS PubMed Google Scholar
• Malfertheiner, P., Chan, F. K. & McColl, K. E. Peptic ulcer disease. Lancet 374, 1449–1461 (2009).
  Article CAS PubMed Google Scholar
• Hunt, R. H. et al. The stomach in health and disease. Gut 64, 1650–1668 (2015). A comprehensive update on all aspects of gastric functions.
  Article CAS PubMed PubMed Central Google Scholar
• Logan, R. P. et al. Changes in the intragastric distribution of H. pylori during treatment with omeprazole. Gut 36, 12–16 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Stolte, M., Meining, A., Schmitz, J. M., Alexandridis, T. & Seifert, E. Changes in _Helicobacter pylori_-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 12, 247–253 (1998).
  Article CAS PubMed Google Scholar
• Kuipers, E. J. et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 334, 1018–1022 (1996).
  Article CAS PubMed Google Scholar
• Eissele, R., Brunner, G., Simon, B., Solcia, E. & Arnold, R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 112, 707–717 (1997).
  Article CAS PubMed Google Scholar
• Lundell, L. et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment. Pharmacol. Ther. 23, 639–647 (2006).
  Article CAS PubMed Google Scholar
• Malfertheiner, P. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66, 6–30 (2017). This manuscript presents the latest recommendations on the management of Helicobacter pylori infection and the role of PPIs.
  Article CAS PubMed Google Scholar
• Sanduleanu, S., Jonkers, D., De Bruïne, A., Hameeteman, W. & Stockbrügger, R. W. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment. Pharmacol. Ther. 8, 1163–1175 (2001).
  Article Google Scholar
• Schulz, C., Koch, N., Schütte, K., Pieper, D. H. & Malfertheiner, P. H. pylori and its modulation of gastrointestinal microbiota. J. Dig. Dis. 16, 109–117 (2015).
  Article PubMed Google Scholar
• Freedberg, D. E. et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149, 883–885 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749–756 (2016). References 37 and 38 provide novel insights into the effect of PPIs on gut microbiota composition.
  Article CAS PubMed Google Scholar
• Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016).
  Article CAS PubMed Google Scholar
• Clooney, A. G. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment. Pharmacol. Ther. 43, 974–984 (2016).
  Article CAS PubMed Google Scholar
• Lombardo, L., Foti, M., Ruggia, O. & Chiecchio, A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin. Gastroenterol. Hepatol. 8, 504–508 (2010).
  Article PubMed Google Scholar
• Ratuapli, S. K. et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am. J. Gastroenterol. 107, 730–735 (2012).
  Article CAS PubMed Google Scholar
• Lo, W. K. & Chan, W. W. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin. Gastroenterol. Hepatol. 11, 483–490 (2013).
  Article CAS PubMed Google Scholar
• Jacobs, C., Coss Adame, E., Attaluri, A., Valestin, J. & Rao, S. S. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment. Pharmacol. Ther. 37, 1103–1111 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Giamarellos-Bourboulis, E. J., Pyleris, E., Barbatzas, C., Pistiki, A. & Pimentel, M. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 16, 67 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047–2056 (2007).
  Article PubMed Google Scholar
• Doorduyn, Y., Van Den Brandhof, W. E., Van Duynhoven, Y. T., Wannet, W. J. & Van Pelt, W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in the Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol. Infect. 134, 617–626 (2006).
  Article CAS PubMed Google Scholar
• Bavishi, C. & Dupont, H. L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment. Pharmacol. Ther. 34, 1269–1281 (2011).
  Article CAS PubMed Google Scholar
• Hassing, R. J., Verbon, A., de Visser, H., Hofman, A. & Stricker, B. H. Proton pump inhibitors and gastroenteritis. Eur. J. Epidemiol. 31, 1057–1063 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Kwok, C. S. et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 107, 1011–1019 (2012).
  Article CAS PubMed Google Scholar
• Tleyjeh, I. M. et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS ONE 7, e50836 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Arriola, V. et al. Assessing the risk of hospital-acquired Clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect. Control Hosp. Epidemiol. 28, 1–10 (2016). A meta-analysis suggesting an almost twofold increased risk of hospital-acquired Clostridium difficile infection in patients on PPIs.
  Google Scholar
• Kandel, C. E., Gill, S. E., McCready, J., Matelski, J. & Powis, J. E. Reducing co-administration of proton pump inhibitors and antibiotics using a computerized order entry alert and prospective audit and feedback. BMC Infect. Dis. 16, 355 (2016).
  Article PubMed PubMed Central Google Scholar
• Chande, N. & Driman, D. K. Microscopic colitis associated with lansoprazole: report of two cases and a review of the literature. Scand. J. Gastroenterol. 42, 530–533 (2007).
  Article CAS PubMed Google Scholar
• Wilcox, G. M. & Mattia, A. R. Microscopic colitis associated with omeprazole and esomeprazole exposure. J. Clin. Gastroenterol. 43, 551–553 (2009).
  Article CAS PubMed Google Scholar
• Keszthelyi, D. et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment. Pharmacol. Ther. 32, 1124–1128 (2010).
  Article CAS PubMed Google Scholar
• Verhaegh, B. P. et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment. Pharmacol. Ther. 43, 1004–1013 (2016).
  Article CAS PubMed Google Scholar
• Xu, H. B. et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet. Mol. Res. 14, 7490–7501 (2015).
  Article CAS PubMed Google Scholar
• Terg, R. et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J. Hepatol. 62, 1056–1060 (2015).
  Article CAS PubMed Google Scholar
• Dam, G., Vilstrup, H., Watson, H. & Jepsen, P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 64, 1265–1272 (2016). A relevant study showing that PPIs increase the risk of developing hepatic encephalopathy and spontaneous bacterial peritonitis in patients with liver cirrhosis.
  Article CAS PubMed Google Scholar
• Fohl, A. L. & Regal, R. E. Proton pump inhibitor-associated pneumonia: not a breath of fresh air after all? World J. Gastrointest. Pharmacol. Ther. 2, 17–26 (2011).
  Article PubMed PubMed Central Google Scholar
• Alshamsi, F. et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit. Care 20, 120 (2016).
  Article PubMed PubMed Central Google Scholar
• Laheij, R. J., Van Ijzendoorn, M. C., Janssen, M. J. & Jansen, J. B. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment. Pharmacol. Ther. 18, 847–851 (2003).
  Article CAS PubMed Google Scholar
• Eom, C. S. et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183, 310–319 (2011).
  Article PubMed PubMed Central Google Scholar
• Filion, K. B. et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 63, 552–558 (2014).
  Article CAS PubMed Google Scholar
• Estborn, L. & Joelson, S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment. Pharmacol. Ther. 42, 607–613 (2015). A large cohort study of a PPI (esomeprazole) that disproves the risk of community-acquired pneumonia.
  Article CAS PubMed Google Scholar
• Abramowitz, J. et al. Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol. Head Neck Surg. 155, 547–554 (2016).
  Article PubMed Google Scholar
• Gomm, W. et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 73, 410–416 (2016). This study was an adverse event report showing a significantly increased risk of incident dementia in conjunction with PPI use; this report caused great concern in the general public.
  Article PubMed Google Scholar
• Booker, A., Jacob, L. E., Rapp, M., Bohlken, J. & Kostev, K. Risk factors for dementia diagnosis in German primary care practices. Int. Psychogeriatr. 28, 1059–1065 (2016).
  Article PubMed Google Scholar
• Clark, D. W. & Strandell, J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur. J. Clin. Pharmacol. 62, 473–479 (2006).
  Article CAS PubMed Google Scholar
• Ruffenach, S. J., Siskind, M. S. & Lien, Y. H. Acute interstitial nephritis due to omeprazole. Am. J. Med. 93, 472–473 (1992).
  Article CAS PubMed Google Scholar
• Perazella, M. A. & Markowitz, G. S. Drug-induced acute interstitial nephritis. Nat. Rev. Nephrol. 6, 461–470 (2010).
  Article CAS PubMed Google Scholar
• Muriithi, A. K. et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am. J. Kidney Dis. 64, 558–566 (2014).
  Article PubMed Google Scholar
• Moledina, D. G., & Perazella, M. A. PPIs and kidney disease: from AIN to CKD. J. Nephrol. 29, 611–616 (2016).
  Article CAS PubMed Google Scholar
• Blank, M. L., Parkin, L., Paul, C. & Herbison, P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 86, 837–844 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Antoniou, T. et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open 3, E166–E171 (2015).
  Article PubMed PubMed Central Google Scholar
• Geevasinga, N., Coleman, P. L., Webster, A. C. & Roger, S. D. Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol. Hepatol. 4, 597–604 (2006).
  Article CAS PubMed Google Scholar
• Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern. Med. 176, 238–246 (2016). This study report comprehensive data showing that PPI use is associated with a low risk of incident chronic kidney disease.
  Article PubMed PubMed Central Google Scholar
• Xie, Y. et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J. Am. Soc. Nephrol. 10, 3153–3163 (2016).
  Article Google Scholar
• Maggio, M. et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern. Med. 173, 518–523 (2013).
  Article PubMed PubMed Central Google Scholar
• Leontiadis, G. I., Sharma, V. K. & Howden, C. W. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin. Proc. 82, 286–296 (2007).
  Article CAS PubMed Google Scholar
• Lam, J. R., Schneider, J. L., Zhao, W. & Corley, D. A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamine B12 deficiency. JAMA 310, 2435–2442 (2013).
  Article CAS PubMed Google Scholar
• McColl, K. E. Effect of proton pump inhibitors on vitamins and iron. Am. J. Gastroenterol. 104, S5–S9 (2009).
  Article CAS PubMed Google Scholar
• Venerito, M. et al. Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis. J. Clin. Pathol. 69, 677–685 (2016).
  Article CAS PubMed Google Scholar
• al-Ghamdi, S. M., Cameron, E. C. & Sutton, R. A. Magnesium deficiency: pathophysiologic and clinical overview. Am. J. Kidney Dis. 24, 737–752 (1994).
  Article CAS PubMed Google Scholar
• Epstein, M., McGrath, S. & Law, F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N. Engl. J. Med. 355, 1834–1836 (2006).
  Article CAS PubMed Google Scholar
• Hoorn, E. J. et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am. J. Kidney Dis. 56, 112–116 (2010).
  Article PubMed Google Scholar
• Mackay, J. D. & Bladon, P. T. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 103, 387–395 (2010).
  Article CAS PubMed Google Scholar
• Luk, C. P., Parsons, R., Lee, Y. P. & Hughes, J. D. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann. Pharmacother. 47, 773–780 (2013).
  Article CAS PubMed Google Scholar
• Quamme, G. A. Recent developments in intestinal magnesium absorption. Curr. Opin. Gastroenterol. 24, 230–235 (2008).
  Article CAS PubMed Google Scholar
• Voets, T. et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J. Biol. Chem. 279, 19–25 (2004).
  Article CAS PubMed Google Scholar
• Schlingmann, K. P. et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat. Genet. 31, 166–170 (2002).
  Article CAS PubMed Google Scholar
• Zipursky, J. et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med. 11, e1001736 (2014). A population-based case–control study showing an increased risk of hospitalization with hypomagnesaemia in patients on PPIs that are also receiving diuretics.
  Article PubMed PubMed Central Google Scholar
• Sumukadas, D., McMurdo, M. E. T. & Habicht, D. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J. Am. Geriatr. Soc. 60, 392–393 (2012).
  Article PubMed Google Scholar
• Danziger, J. et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 83, 692–699 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Misra, P. S., Alam, A., Lipman, M. L. & Nessim, S. J. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrol. 16, 136 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Sharara, A. I. et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. Clin. Gastroenterol. Hepatol. 14, 317–321 (2016). An important study showing that, in the absence of known precipitating factors (concomitant diuretic intake, chronic diarrhoea, chronic kidney disease and malignancies), chronic PPI use is not associated with hypomagnesaemia.
  Article CAS PubMed Google Scholar
• Biyik, M. et al. Hypomagnesemia among outpatient long-term proton pump inhibitor users. Am. J. Ther. 24, e52–e55 (2017).
  Article PubMed Google Scholar
• Negri, A. L. & Valle, E. E. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. Curr. Drug Saf. 6, 204–206 (2011).
  Article CAS PubMed Google Scholar
• Deroux, A., Khouri, C., Chabre, O., Bouillet, L. & Casez, O. Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. Clin. Res. Hepatol. Gastroenterol. 38, e103–e105 (2014).
  Article CAS PubMed Google Scholar
• Leontiadis, G. I. & Moayyedi, P. Proton pump inhibitors and risk of bone fractures. Curr. Treat. Options Gastroenterol. 12, 414–423 (2014).
  Article PubMed Google Scholar
• Thongon, N. & Krishnamra, N. Apical acidity decreases inhibitory effect of omeprazole on Mg(2+) absorption and claudin-7 and -12 expression in Caco-2 monolayers. Exp. Mol. Med. 44, 684–693 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Lameris, A. L. L., Hess, M. W., van Kruijsbergen, I., Hoenderop, J. G. J. & Bindels, R. J. M. Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6. Pflugers Arch. 465, 1613–1620 (2013).
  Article CAS PubMed Google Scholar
• Hess, M. W., de Baaij, J. H. F., Gommers, L. M. M., Hoenderop, J. G. J. & Bindels, R. J. M. Dietary inulin fibers prevent proton-pump inhibitor (PPI)-induced hypocalcemia in mice. PLoS ONE 10, e0138881 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Wright, M. J. et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J. Bone Miner. Res. 25, 2205–2211 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hansen, K. E. et al. Do proton pump inhibitors decrease calcium absorption? J. Bone Miner. Res. 25, 2786–2795 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Attwood, S. E. et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment. Pharmacol. Ther. 41, 1162–1174 (2015). This study shows data from controlled randomized trials with reassuring findings on long-term PPI use, electrolytes and micronutrients.
  Article CAS PubMed Google Scholar
• Vestergaard, P., Rejnmark, L. & Mosekilde, L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue Int. 79, 76–83 (2006).
  Article CAS PubMed Google Scholar
• Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947–2953 (2006).
  Article CAS PubMed Google Scholar
• Targownik, L. E. et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179, 319–326 (2008).
  Article PubMed PubMed Central Google Scholar
• Ye, X. et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 9, 794–800 (2011).
  Article CAS Google Scholar
• Ngamruengphong, S., Leontiadis, G., Radhi, S., Dentino, A. & Nugent, K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am. J. Gastroenterol. 106, 1209–1218 (2011).
  Article CAS PubMed Google Scholar
• Corley, D. A., Kubo, A., Zhao, W. & Quesenberry, C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139, 93–101 (2010).
  Article PubMed PubMed Central Google Scholar
• Kaye, J. A. & Jick, H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28, 951–959 (2008).
  Article CAS PubMed Google Scholar
• Targownik, L. E., Lix, L. M., Leung, S. & Leslie, W. D. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138, 896–904 (2010). An accurate study shedding light on the association between PPIs and osteoporosis or accelerated bone mineral density loss.
  Article CAS PubMed Google Scholar
• Chen, C. H., Lin, C. L. & Kao, C. H. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos. Int. 27, 2117–2126 (2016).
  Article CAS PubMed Google Scholar
• Serbin, M. A., Guzauskas, G. F. & Veenstra, D. L. Clopidogrel-proton pump inhibitor drug-drug interaction and risk of adverse clinical outcomes among PCI-treated ACS patients: a meta-analysis. J. Manag. Care Spec. Pharm. 22, 939–947 (2016). A meta-analysis of randomized controlled trials and observational studies, showing that concomitant clopidogrel–PPI therapy following percutaneous coronary intervention is significantly associated with adverse cardiovascular events.
  PubMed PubMed Central Google Scholar
• Sherwood, M. W. et al. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J. Am. Heart Assoc. 4, e002245 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Melloni, C. et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ. Cardiovasc. Qual. Outcomes 8, 47–55 (2015).
  Article PubMed PubMed Central Google Scholar
• Gilard, M., Arnaud, B., le Gal, G., Abgrall, J. F. & Boschat, J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost. 4, 2508–2509 (2006).
  Article CAS PubMed Google Scholar
• Focks, J. J. et al. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome: a systematic review. Heart 99, 520–527 (2013).
  Article PubMed Google Scholar
• Siller-Matula, J. M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1–148.e5 (2009).
  Article CAS Google Scholar
• Small, D. S. et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 48, 475–484 (2008).
  Article CAS PubMed Google Scholar
• Bhatt, D. L., et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363, 1909–1917 (2010).
  Article CAS PubMed Google Scholar
• Gao, Q. P. Sun, Y., Sun, Y. X., Wang, L. F. & Fu, L. Early use of omeprazole benefits patients with acute myocardial infarction. J. Thromb. Thrombolysis 28, 282–287 (2009).
  Article CAS PubMed Google Scholar
• FDA. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole. FDA https://www.fda.gov/Drugs/DrugSafety/ucm231161.htm (2016).
• Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363–375 (2009).
  Article CAS PubMed Google Scholar
• Rosemary, J. & Adithan, C. The pharmacogenetics of CYP 2C9 and CYP2C19: ethnic variation and clinical significance. Curr. Clin. Pharmacol. 2, 93–109 (2007).
  Article CAS PubMed Google Scholar
• Venerito, M., Kandulski, A. & Malfertheiner, P. Dilemma between gastroprotection and cardiovascular prevention. Dtsch. Med. Wochenschr. 135, 2193–2198 (2010).
  Article CAS PubMed Google Scholar
• Depta, J. P. et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J. 15, 20–25 (2015).
  Article CAS PubMed Google Scholar
• Laine, L. & Hennekens, C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am. J. Gastroenterol. 105, 34–41 (2010).
  Article CAS PubMed Google Scholar
• FDA. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). FDA https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm (2009).
• Lahner, E., Annibale, B. & Delle Fave, G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment. Pharmacol. Ther. 29, 1219–1229 (2009).
  Article CAS PubMed Google Scholar
• Julkunen, R. J. The absorption of warfarin from the rat stomach in situ. Med. Biol. 54, 260–263 (1976).
  CAS PubMed Google Scholar
• Scarpignato, C. et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 14, 179 (2016). A position statement on the benefits, harms and appropriateness of PPI use.
  Article CAS PubMed PubMed Central Google Scholar
• Vakily, M., Lee, R. D., Wu, J., Gunawardhana, L. & Mulford, D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin. Drug Investig. 29, 35–50 (2009).
  Article CAS PubMed Google Scholar
• Henriksen, D. P. et al. The potential drug-drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol. Drug Saf. 24, 1337–1340 (2015).
  Article CAS PubMed Google Scholar
• Ha, V. H. et al. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J. Oncol. Pharm. Pract. 21, 194–200 (2015).
  Article CAS PubMed Google Scholar
• Chu, M. P. et al. Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin. Lung Cancer 16, 33–39 (2015).
  Article CAS PubMed Google Scholar
• van Leeuwen, R. W. et al. Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 34, 1309–1314 (2016).
  Article CAS PubMed Google Scholar
• Chu, M. P. et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol. 3, 767–773 (2017). A secondary analysis of a phase III randomized trial, showing that PPIs negatively affect capecitabine efficacy, possibly by raising gastric pH levels; PPI-treated patients with advanced gastro-oesophageal cancer receiving capecitabine-based polychemotherapy had poorer progression-free survival and overall survival than those not treated with PPIs.
  Article PubMed Google Scholar
• Scheulen, M. E. et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 69, 753–761 (2012).
  Article CAS PubMed Google Scholar
• Ghebremariam, Y. T. et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128, 845–853 (2013).
  Article CAS PubMed Google Scholar
• Wilson, A. M. et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc. Med. 15, 267–274 (2010).
  Article PubMed PubMed Central Google Scholar
• Böger, R. H. et al. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J. Intern. Med. 269, 349–361 (2011).
  Article CAS PubMed Google Scholar
• Ghebremariam, Y. T. et al. Proton pump inhibitors and vascular function: a prospective cross-over pilot study. Vasc. Med. 4, 309–316 (2015).
  Article CAS Google Scholar
• Yepuri, G. et al. Proton pump inhibitors accelerate endothelial senescence. Circ. Res. 118, e36–e42 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Goligorsky, M. S. Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a retrospective and what the future may hold. Kidney Res. Clin. Pract. 34, 76–82 (2015).
  Article PubMed PubMed Central Google Scholar
• Di Marco, L. Y. et al. Vascular dysfunction in the pathogenesis of Alzheimer's disease — a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol. Dis. 82, 593–606 (2015).
  Article CAS PubMed Google Scholar
• Flammer, A. J. et al. The assessment of endothelial function: from research into clinical practice. Circulation 126, 753–767 (2012).
  Article PubMed PubMed Central Google Scholar
• Malfertheiner, P. et al. Management of Helicobacter pylori infection — the Maastricht IV/ Florence Consensus Report. Gut 61, 646–664 (2012).
  Article CAS PubMed Google Scholar